Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of the ...
Decision-making inherently involves cause–effect relationships that introduce causal challenges. We argue that reliable algorithms for decision-making need to build upon causal reasoning. Addressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results